154 related articles for article (PubMed ID: 32351139)
1. Efficacy of anti-TNFα drugs in patients with stricturing Crohn's disease.
D'Amico F; Pugliese N; Peyrin-Biroulet L; Danese S
Expert Rev Gastroenterol Hepatol; 2020 May; 14(5):347-353. PubMed ID: 32351139
[TBL] [Abstract][Full Text] [Related]
2. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
3. Anti-TNF-alpha treatments and obstructive symptoms in Crohn's disease: a prospective study.
Condino G; Calabrese E; Zorzi F; Onali S; Lolli E; De Biasio F; Ascolani M; Pallone F; Biancone L
Dig Liver Dis; 2013 Mar; 45(3):258-62. PubMed ID: 23195667
[TBL] [Abstract][Full Text] [Related]
4. Medical Therapies for Stricturing Crohn's Disease: Efficacy and Cross-Sectional Imaging Predictors of Therapeutic Failure.
Campos C; Perrey A; Lambert C; Pereira B; Goutte M; Dubois A; Goutorbe F; Dapoigny M; Bommelaer G; Hordonneau C; Buisson A
Dig Dis Sci; 2017 Jun; 62(6):1628-1636. PubMed ID: 28401425
[TBL] [Abstract][Full Text] [Related]
5. [Anti-TNF antibodies in the treatment of inflammatory intestinal stenoses in Crohn's disease].
Holtmann M; Wanitschke R; Helisch A; Bartenstein P; Galle PR; Neurath M
Z Gastroenterol; 2003 Jan; 41(1):11-7. PubMed ID: 12541166
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
Yang E; Panaccione N; Whitmire N; Dulai PS; Vande Casteele N; Singh S; Boland BS; Collins A; Sandborn WJ; Panaccione R; Battat R
Aliment Pharmacol Ther; 2020 Jun; 51(11):1031-1038. PubMed ID: 32329532
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.
Narula N; Kainz S; Petritsch W; Haas T; Feichtenschlager T; Novacek G; Eser A; Vogelsang H; Reinisch W; Papay P
Aliment Pharmacol Ther; 2016 Jul; 44(2):170-80. PubMed ID: 27226407
[TBL] [Abstract][Full Text] [Related]
9. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
[TBL] [Abstract][Full Text] [Related]
11. [Anti-TNF therapy in treatment of luminal Crohn's disease].
Marko B; Prka L
Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301
[TBL] [Abstract][Full Text] [Related]
12. Role of biologics and other therapies in stricturing Crohn's disease: what have we learnt so far?
Sorrentino D
Digestion; 2008; 77(1):38-47. PubMed ID: 18285676
[TBL] [Abstract][Full Text] [Related]
13. Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn's disease.
Rodríguez-Lago I; Hoyo JD; Pérez-Girbés A; Garrido-Marín A; Casanova MJ; Chaparro M; Fernández-Clotet A; Castro-Poceiro J; García MJ; Sánchez S; Ferreiro-Iglesias R; Bastón I; Piqueras M; Careda LEIB; Mena R; Suárez C; Cordón JP; López-García A; Márquez L; Arroyo M; Alfambra E; Sierra M; Cano N; Delgado-Guillena P; Morales-Alvarado V; Aparicio JC; Guerra I; Aulló C; Merino O; Arranz L; Hidalgo MA; Llaó J; Plaza R; Molina G; Torres P; Pérez-Galindo P; Romero MG; Herrera-deGuise C; Armesto E; Mesonero F; Frago-Larramona S; Benítez JM; Calvo M; Martín MDCL; Elorza A; Larena A; Peña E; Rodríguez-Grau MDC; Miguel-Criado J; Botella B; Olmos JA; López L; Aguirre U; Gisbert JP;
United European Gastroenterol J; 2020 Nov; 8(9):1056-1066. PubMed ID: 32723069
[TBL] [Abstract][Full Text] [Related]
14. Infliximab treatment for symptomatic Crohn's disease strictures.
Pelletier AL; Kalisazan B; Wienckiewicz J; Bouarioua N; Soulé JC
Aliment Pharmacol Ther; 2009 Feb; 29(3):279-85. PubMed ID: 19035967
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
Trinder MW; Lawrance IC
J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
[TBL] [Abstract][Full Text] [Related]
16. Infliximab and pediatric stricturing Crohn's disease: a possible alternative to surgery? Experience of seven cases.
Gasparetto M; Corradin S; Vallortigara F; Cananzi M; Guariso G
Acta Gastroenterol Belg; 2012 Mar; 75(1):58-60. PubMed ID: 22567750
[TBL] [Abstract][Full Text] [Related]
17. Fourteen-Year Anti-TNF Therapy in Crohn's Disease Patients: Clinical Characteristics and Predictive Factors.
Osamura A; Suzuki Y
Dig Dis Sci; 2018 Jan; 63(1):204-208. PubMed ID: 29209921
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
Zorzi F; Zuzzi S; Onali S; Calabrese E; Condino G; Petruzziello C; Ascolani M; Pallone F; Biancone L
Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series.
Cordero Ruiz P; Castro Márquez C; Méndez Rufián V; Castro Laria L; Caunedo Álvarez A; Romero Vázquez J; Herrerías Gutiérrez JM
Rev Esp Enferm Dig; 2011 Jun; 103(6):294-8. PubMed ID: 21736395
[TBL] [Abstract][Full Text] [Related]
20. Infliximab use in luminal Crohn's disease.
Richter JA; Bickston SJ
Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]